ASLAN Pharmaceuticals Presents New Data From Phase 2b Study Of Eblasakimab In Atopic Dermatitis In Late Breaker Presentation At 32nd European Academy Of Dermatology And Venereology Congress
Portfolio Pulse from Benzinga Newsdesk
ASLAN Pharmaceuticals presented new data from a Phase 2b study of Eblasakimab in Atopic Dermatitis at the 32nd European Academy of Dermatology and Venereology Congress. The data shows Eblasakimab's potential as the first biologic in moderate-to-severe atopic dermatitis with a competitive efficacy profile with once-monthly dosing. A post-hoc analysis of patients with severe disease showed a 74.5% reduction in EASI score with 600 mg Eblasakimab for 16 weeks.
October 13, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ASLAN Pharmaceuticals' new data from a Phase 2b study of Eblasakimab shows promising results, potentially positioning the company favorably in the atopic dermatitis market.
The positive results from the Phase 2b study of Eblasakimab presented by ASLAN Pharmaceuticals could potentially boost the company's stock. The data shows Eblasakimab's potential as the first biologic in moderate-to-severe atopic dermatitis with a competitive efficacy profile. This could position the company favorably in the atopic dermatitis market, leading to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100